CEACAM5 and colorectal carcinoma: In this sense, further research is guaranteed to try to determine whether ∆Np73 seroreactivity would reflect chronic inflammation (like CEA or CA19-9) or whether it is more specific of colorectal premalignant lesions than that of CRC as our results suggest, and more importantly to assess the actual clinical management utility of ∆Np73 seroreactivity by determining its association with clinic-pathological parameters, which might help identifying patients with higher risk of cancer progression and also assist in selecting the most efficient personalized treatments.